MX2010002523A - Compuestos de piperidinilamino-tieno[2,3-d] pirimidina para tratar la fibrosis. - Google Patents

Compuestos de piperidinilamino-tieno[2,3-d] pirimidina para tratar la fibrosis.

Info

Publication number
MX2010002523A
MX2010002523A MX2010002523A MX2010002523A MX2010002523A MX 2010002523 A MX2010002523 A MX 2010002523A MX 2010002523 A MX2010002523 A MX 2010002523A MX 2010002523 A MX2010002523 A MX 2010002523A MX 2010002523 A MX2010002523 A MX 2010002523A
Authority
MX
Mexico
Prior art keywords
piperidinylamino
thieno
pyrimidine compounds
treating fibrosis
modulator
Prior art date
Application number
MX2010002523A
Other languages
English (en)
Inventor
Kimberley Gannon
Philip B Graham
Original Assignee
Epix Delaware Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Delaware Inc filed Critical Epix Delaware Inc
Publication of MX2010002523A publication Critical patent/MX2010002523A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La invención presenta un método para tratar o prevenir fibrosis en un individuo mediante la administración de un modulador 5-HT, por ejemplo, un modulador 5-HT2B. En modalidades particulares, el modulador 5-HT es un compuesto piperidilamino-tien(2,3-d)pirimidin a.
MX2010002523A 2007-09-04 2008-09-04 Compuestos de piperidinilamino-tieno[2,3-d] pirimidina para tratar la fibrosis. MX2010002523A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96982007P 2007-09-04 2007-09-04
PCT/US2008/075193 WO2009032885A2 (en) 2007-09-04 2008-09-04 Piperidinylamino-thieno[2,3-d] pyrimidine compounds for treating fibrosis

Publications (1)

Publication Number Publication Date
MX2010002523A true MX2010002523A (es) 2010-08-31

Family

ID=40291329

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002523A MX2010002523A (es) 2007-09-04 2008-09-04 Compuestos de piperidinilamino-tieno[2,3-d] pirimidina para tratar la fibrosis.

Country Status (11)

Country Link
US (1) US20100280050A1 (es)
EP (1) EP2194988A2 (es)
JP (1) JP2010538078A (es)
KR (1) KR20100072008A (es)
CN (1) CN101820882A (es)
AU (1) AU2008296308A1 (es)
BR (1) BRPI0816464A2 (es)
CA (1) CA2698377A1 (es)
EA (1) EA201070334A1 (es)
MX (1) MX2010002523A (es)
WO (1) WO2009032885A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9271980B2 (en) * 2009-08-03 2016-03-01 Daljit Singh Dhanoa Deuterium-enriched pyrimidine compounds and derivatives
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
EP3233799B1 (en) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030240B2 (en) * 2003-03-31 2006-04-18 Predix Pharmaceuticals Holdings, Inc. Piperidinylamino-thieno[2,3-d] pyrimidine compounds
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US20070213305A1 (en) * 2005-11-02 2007-09-13 Cytovia, Inc. N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20080108611A1 (en) * 2006-01-19 2008-05-08 Battista Kathleen A Substituted thienopyrimidine kinase inhibitors

Also Published As

Publication number Publication date
AU2008296308A1 (en) 2009-03-12
BRPI0816464A2 (pt) 2015-03-24
CN101820882A (zh) 2010-09-01
JP2010538078A (ja) 2010-12-09
WO2009032885A3 (en) 2009-04-30
EP2194988A2 (en) 2010-06-16
KR20100072008A (ko) 2010-06-29
WO2009032885A2 (en) 2009-03-12
EA201070334A1 (ru) 2010-10-29
US20100280050A1 (en) 2010-11-04
CA2698377A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
MX358682B (es) Derivados de pirazolo [1,5a]pirimidina y de tieno[3,2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
MY146989A (en) Kinase inhibitors
TW200626068A (en) Active compounds for seed treatment
MX2009009290A (es) Compuestos activos en ppar.
WO2008083252A3 (en) Methods of use for cyclopamine analogs
MY152162A (en) Imidazole based lxr modulators
TN2012000248A1 (en) Novel spiropiperidine compounds
UA94833C2 (en) Substituted bicyclolactams
MY156254A (en) Salts and polymorphs of a tetracycline compound
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
TW200619206A (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
MY144782A (en) Glucuronate salt of a piperazine compound
MX2008007808A (es) Analogos de rifamicina y usos de ellos.
WO2010066629A3 (en) Novel azaindoles
GB2466912A (en) Compositions and methods for treating lysosomal disorders
SG162803A1 (en) Imidazole based lxr modulators
WO2008053334A3 (en) An improved process for preparing rosuvastatin calcium
WO2010021934A3 (en) Azaindole inhibitors of iap
MX2010005809A (es) Proceso de dehidrohalogenacion para la preparacion de intermediarios utiles en el suministro de compuestos 6,6-dimetil-3-azabiciclo-[3,1,0]-hexano.
TW200637832A (en) Process for preparing amorphous valsartan
MX2008011576A (es) Compuestos de imidazo[2,1-b]tiazol sustituidos y su uso para la produccion de farmacos.
WO2006124865A3 (en) Biaryls derivatives useful as modulators of ion channels
MX2010001938A (es) Metodos para preparar compuestos basados en 4-fenil-6-(2,2,2-trifl uoro-1-feniletoxi)pirimidina.
MX2010002523A (es) Compuestos de piperidinilamino-tieno[2,3-d] pirimidina para tratar la fibrosis.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: TROVIS PHARMACEUTICALS LLC

HC Change of company name or juridical status

Owner name: TROVIS PHARMACEUTICALS LLC

FA Abandonment or withdrawal